INTRODUCTION
Osteoporosis therapy is the focus of attention of significant R&D
activity, with drugs in development both in existing classes offering advantages
over marketed products and novel drugs exploiting genomics programs and a deeper
understanding of bone biology.
SCOPE OF THE REPORT
- Epidemiology of osteoporosis in the seven major markets by disease
severity, identification of niche populations and unmet needs
- Detailed profiles of drugs in Phase II and above - clinical data, patient
potential, marketing factors, satisfaction of unmet needs
- Primary research with key osteoporosis opinion leaders providing insight
on future market entrants and innovative R&D projects in the disease
area
- Global sales forecasts for key pipeline drugs, currently marketed products
and classes
REPORT HIGHLIGHTS
Novel bisphosphonates, Zometa and Boniva, with innovative dosing regimens and
delivery methods, will lead growth in the osteoporosis market; R&D
osteoporosis drugs will reach sales of $4.7 billion by 2011.
Driven by new
market leader Evista, which will lead Pfizer's lasofoxifene and Wyeth's
bazedoxifene by targeting multiple indications, the SERMs drug class will be
valued at $4.2 billion by 2011.
The early-stage pipeline consists largely of
drug candidates in new therapeutic classes, in particular cathepsin K
inhibitors, osteoprotegerin and calcilytics. While these drugs have the
potential to change the face of osteoporosis treatment in the long term,
innovative approaches will likely be costly to patients, limiting potential.
KEY REASONS TO BUY THIS REPORT
- Validate internal forecasts against drug/class sales model and assess
market potential for pipeline products
- Analyze competitive environment at time of product launch to inform best
strategy for market entry
- Highlight key R&D trends and company involvement in the market to
inform licensing decisions and identify potential partners based on R&D
activity
View Cart
